373604-28-5

Basic information

• Product Name: 1-PIPERIDINECARBOXYLIC ACID, 3-FLUORO-4-HYDROXY-, 1,1-DIMETHYLETHYL ESTER
• Synonyms: 1-PIPERIDINECARBOXYLIC ACID, 3-FLUORO-4-HYDROXY-, 1,1-DIMETHYLETHYL ESTER;tert-Butyl 3-fluoro-4-hydroxypiperidine-1-carboxylate;benzyl 3-fluoro-4-hydro×ypiperidine-1-carbo×ylate;tert-butyl 3-fluoro-4-hydro×ypiperidine-1-carbo×ylate;3-Fluoro-4-hydroxy-1-piperidinecarboxylic Acid 1,1-DiMethylethyl Ester;3-Fluoro-4-hydroxy-1-piperidinecarboxylic Acid tert-Butyl Ester (Mixture of DiastereoMers);3-Fluoro-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester;(3.4)-cis-3-FLUORO-4-HYDROXY-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• CAS NO: 373604-28-5
• Molecular Formula: C₁₀H₁₈FNO₃
• Molecular Weight: 219.254
• Mol File: 373604-28-5.mol

Chemical Properties

• Boiling Point: 300.795 °C at 760 mmHg
• Flash Point: 135.717 °C
• Appearance: /
• Density: 1.156 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-PIPERIDINECARBOXYLIC ACID, 3-FLUORO-4-HYDROXY-, 1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PIPERIDINECARBOXYLIC ACID, 3-FLUORO-4-HYDROXY-, 1,1-DIMETHYLETHYL ESTER(373604-28-5)
• EPA Substance Registry System: 1-PIPERIDINECARBOXYLIC ACID, 3-FLUORO-4-HYDROXY-, 1,1-DIMETHYLETHYL ESTER(373604-28-5)

Safety Data

• Hazardous Substances Data: 373604-28-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-PIPERIDINECARBOXYLIC ACID, 3-FLUORO-4-HYDROXY-, 1,1-DIMETHYLETHYL ESTER is used as a key intermediate compound for the preparation of therapeutic GPR 119 modulators. GPR 119 is a G protein-coupled receptor that plays a role in glucose homeostasis and has been identified as a potential target for the treatment of type 2 diabetes and obesity. 1-PIPERIDINECARBOXYLIC ACID, 3-FLUORO-4-HYDROXY-, 1,1-DIMETHYLETHYL ESTER's unique structure allows it to interact with GPR 119, modulating its activity and potentially leading to improved glucose control and weight management in patients.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 211108-48-4 tert-butyl 4-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 
• 211108-50-8 tert-butyl-3-fluoro-4-oxopiperidine-1-carboxylate 

Downstream Products

• 1070896-84-2 (anti)-3-fluoro-4-methanesulfonyloxypiperidine-1-carboxylic acid tert-butyl ester 
• 577691-56-6 cis-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 1070896-84-2 tert-butyl 3-fluoro-4-((methylsulfonyl)oxy)piperidine-1-carboxylate 
• 1450879-65-8 tert-butyl (3R,4S)-3-fluoro-4-[[(4-methylbenzene)sulfonyl]oxy]piperidine-1-carboxylate 
• 1450879-66-9 (3S,4R)-tert-butyl 3-fluoro-4-(tosyloxy)piperidine-1-carboxylate 
• 577691-56-6 (3S,4S)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 1260612-08-5 (3R,4R)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 211108-52-0 (3S,4S)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 211108-52-0 (3R,4R)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 934536-09-1 tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 

Relevant articles and documents

SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention provides novel spiro[cyclobutane-1,3'-indolin]-2'- derivatives of formula (I) in which Cy R1, R2, R4, L and 'm' are have the meaning given in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as bromodomain inhibitors in the treatment or prevention of diseases or disorders where bromodomain inhibition is desired.

PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS

The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors wherein X, ring A, ring B, L1, L2, R1,R2, R3, R4, R6, m, n and p have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

The present invention relates to compounds of formula I in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS

The present invention provides heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines of Formula I: wherein X, Y, Z, L, A, R5, n, m, and r are defined above, as well as their compositions and methods of use, that modulate the activity

IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS

Compounds of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5 R6, R7 and R8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention have also been found to be inhibitors of Pim-1.